Princess Margaret Cancer Centre (UHN) | Toronto, Canada

Zusammenfassung

Princess Margaret is an academic cancer centre affiliated with the University of Toronto. Its work includes breast, lung, prostate, colorectal, blood, head and neck cancers, and sarcoma. Relevant programmes include early-phase drug development, personalised cancer medicine, genomics and stem cell transplantation. Treatment options may include immunotherapy, targeted therapy, radiation therapy, surgery and CAR-T therapy for eligible patients. An indicative figure of around 300 active oncology clinical trials describes the scale of its research activity, not the number currently recruiting or accessible to international patients. Prospective patients need to confirm referral acceptance, treatment availability, financial arrangements and continuity of care at home; inclusion in a clinical trial requires a separate eligibility assessment.

Das Wichtigste

Princess Margaret is a specialist cancer centre within UHN in Toronto, with academic links to the University of Toronto.
Its programmes cover common solid tumours, blood cancers and less common cancers such as sarcoma.
Genomic testing may inform treatment selection, but an actionable result does not guarantee access to a matched therapy.
The Drug Development Program evaluates investigational treatments, including through phase I trials.
CAR-T therapy and stem cell transplantation require specialist assessment and confirmation of international patient access.
International patients should secure clinical acceptance and financial clarification before booking travel.

Überblick

Princess Margaret opened as Princess Margaret Hospital in 1958 and is now part of University Health Network. It combines cancer diagnosis, treatment, research and professional education within Toronto’s academic healthcare system, with an affiliation to the University of Toronto.

The centre has a substantial cancer research programme spanning laboratory science, translational research and clinical trials. Care is organised around disease-specific teams, allowing specialists to consider pathology, imaging, surgery, radiation and drug treatment together where appropriate.

Princess Margaret is known for early drug development, personalised cancer medicine and genomics, as well as programmes in blood cancers and stem cell transplantation. Its Drug Development Program studies investigational agents, including treatments being evaluated in early human trials. These research activities complement established treatment rather than replacing it.

Patients may receive parts of their care at different UHN facilities. Surgical care, diagnostic procedures, inpatient treatment and outpatient appointments need not all occur in the same building. International patients should ask which locations and services their proposed pathway would involve.

Schwerpunkte

Disease-specific programmes include breast, lung, prostate and colorectal cancers. Assessment considers cancer stage, tumour biology, previous treatment and general health. Depending on the diagnosis, care may involve local treatment with surgery or radiation, systemic medication, or a combination. These programmes address both earlier-stage disease and advanced cancer, although the options for an individual patient require specialist review.

Blood cancer services cover conditions such as leukaemia, lymphoma and myeloma, with specialist consideration of transplantation and cellular therapies where appropriate. Head and neck cancer care may require coordinated surgery, radiation, systemic therapy, nutrition and rehabilitation. Sarcoma assessment depends particularly on expert pathology review and multidisciplinary planning because these cancers comprise many distinct subtypes. The centre’s programme coverage should not be interpreted as evidence that every rare subtype or proposed intervention is available to an overseas patient.

Verfügbare Behandlungen

Surgery and radiation therapy are components of cancer care at Princess Margaret and across UHN. Their role depends on tumour location, stage and treatment goals. Radiation may be used with curative intent, alongside other treatment, or to relieve symptoms. The team should explain the expected benefit, important risks and likely treatment schedule.

Systemic treatments include chemotherapy, hormone therapy for relevant cancers, targeted therapy and immunotherapy. Targeted drugs may require a specific molecular alteration, while immunotherapy eligibility varies by cancer type and clinical setting. Genomic profiling can sometimes identify treatment or trial possibilities, but it may also produce findings without an established therapeutic option.

CAR-T therapy is available for selected blood cancer indications, subject to specialist eligibility assessment and programme access. Stem cell transplantation is another specialised option for certain blood cancers. Both can involve intensive treatment, significant complications, caregiver requirements and prolonged monitoring; international availability must be confirmed rather than assumed.

Supportive and palliative care can accompany active cancer treatment to address symptoms, function and quality of life. International patients should ask how these services, emergency care and management of treatment complications would be arranged. A plan should also specify which follow-up can safely occur with the patient’s home oncology team.

Klinische Studien

An indicative figure of around 300 active oncology clinical trials reflects the scale of Princess Margaret’s research portfolio. Trial numbers change, and “active” can include studies that are no longer enrolling new participants. The Drug Development Program includes phase I research, which commonly examines safety, dose and early signs of anticancer activity. Participation does not guarantee benefit.

International patients can ask whether their records may be reviewed for relevant studies, but routine treatment acceptance does not establish trial eligibility. Criteria may include cancer subtype, biomarkers, previous therapies, organ function and ability to attend repeated visits. Recruitment status, available places and arrangements for non-resident participants must be checked directly. Patients should clarify which study procedures are funded and which routine care, travel or complication-related expenses remain their responsibility. Trial consent should explain risks, alternatives and the right to withdraw.

Praktische Hinweise für internationale Patientinnen und Patienten

Begin with the centre’s official referral information and ask which UHN process applies to international patients. Provide a concise medical history and establish whether a clinician can assess the case before travel. Do not assume that sending records constitutes acceptance, or that a preliminary opinion confirms a treatment or trial place.

Before committing to care, obtain a proposed clinical pathway and written financial information. Confirm the likely period in Toronto, caregiver expectations, accommodation needs and arrangements if treatment is delayed or complications occur. Ask your treating team at home to help plan safe travel, any treatment needed while awaiting review, and follow-up after return. Avoid interrupting effective treatment solely to pursue an unconfirmed overseas option.

Kontaktinformationen

Contact details below come from the hospital's own published international patient information.

Location: Toronto, Canada

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +1 416 946 4501

Website: https://www.uhn.ca/PrincessMargaret

Languages supported: English, French

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.

Fragen von Patientinnen und Patienten

Can you accept my case as an international patient, and what referral route applies?
Which pathology materials, scans and translated records are needed before assessment?
What treatment do you recommend, and how does it compare with options at home?
Are any relevant trials recruiting and able to consider non-resident patients?
What does the financial estimate include, and which additional charges could arise?
How long might I need to remain in Toronto, and will I need a caregiver?
How will urgent complications and follow-up after returning home be managed?

Häufige Fragen

How does an international patient request a referral?

Start with Princess Margaret’s official website and confirm the current UHN route for international patient enquiries. Ask whether a referral from your treating doctor is required and whether the relevant disease team can review your case before travel. Acceptance depends on clinical suitability, service capacity and administrative arrangements. Request written confirmation of what has been accepted: a consultation, diagnostic review, treatment assessment or a specific care plan. These are not interchangeable, and none automatically confirms a clinical trial place.

Which medical records should I prepare?

Commonly requested materials include a referral letter, diagnosis and staging information, pathology reports, scan reports and the underlying imaging files. Include details of previous surgery, radiation and drug treatment, with dates, responses and significant side effects. Recent blood tests, molecular testing results, a medication list and relevant medical conditions may also be needed. Ask whether pathology slides or tissue blocks are required for review, which secure transfer method to use, and whether documents need professional English translation.

What should I expect regarding treatment costs?

International patients should not assume that Canadian public healthcare will cover their care. Ask UHN to explain the applicable financial arrangements and provide an individual written estimate after clinical review. Clarify whether consultations, pathology review, imaging, medicines, hospital stays and supportive care are included. Complications or changes in treatment can alter the total. Confirm insurance authorisation requirements directly with your insurer. Clinical trial participation does not necessarily cover standard cancer care, accommodation, travel or treatment outside the study protocol.

Is language support available?

Ask the centre what professional interpretation can be arranged for your preferred language, including consultations, consent discussions and urgent communication. Confirm how to request it, whether advance notice is needed and whether any charges apply. Availability should be checked for your particular appointment rather than assumed. Written translation of medical records is a separate issue and may need to be arranged before assessment. A relative can provide support, but professional interpretation is preferable for complex treatment decisions and informed consent.

How should I plan travel and accommodation?

Wait for clinical acceptance and a sufficiently clear appointment or treatment plan before making non-refundable bookings. Ask how frequently visits will occur, whether you must stay near the hospital and whether a caregiver is required. Intensive therapies may involve unpredictable admissions or an extended local monitoring period. Confirm entry requirements through official Canadian sources and discuss fitness to fly with your doctor. Ask the centre about accommodation guidance, accessible transport and practical support, without assuming that lodging or travel will be funded.

Quellen

1.Princess Margaret Cancer Centre— University Health Network
2.General information on cancer treatments and clinical trials— National Cancer Institute
3.General oncology guidance and patient resources— European Society for Medical Oncology

GetOnco AI fragen

Erhalten Sie persönliche Antworten zu „Princess Margaret Cancer Centre (UHN) | Toronto, Canada“ von Ihrem KI-Koordinator für Krebsversorgung.

GetOnco AI liefert Informationen zu Bildungszwecken und ersetzt niemals den Rat Ihres Behandlungsteams.